NCT05214690View on ClinicalTrials.gov

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

September 8, 2020

Study Completion Date

September 8, 2020

Conditions
OsteoarthritisRheumatoid ArthritisBack PainAcute Upper Respiratory Tract Infection
Interventions
DRUG

DW1809-T2

pelubiprofen 25mg

DRUG

DW1809-1

pelubiprofen 30mg (PELUBI tab.)

Trial Locations (1)

Unknown

Chungbuk National University Hospital, Cheongju-si

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

NCT05214690 - A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2 | Biotech Hunter | Biotech Hunter